Helge Gydesen

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population.

Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy

Published: February 10, 2021

Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population.

Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population.

Journal: Diabetes, obesity & metabolism

Published: December 12, 2018

Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real-world studies.

Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real-world studies.

Journal: Diabetes, obesity & metabolism

Published: July 25, 2018

Regional variations in definitions and rates of hypoglycaemia: findings from the global HAT observational study of 27 585 people with Type 1 and insulin-treated Type 2 diabetes mellitus.

Regional variations in definitions and rates of hypoglycaemia: findings from the global HAT observational study of 27 585 people with Type 1 and insulin-treated Type 2 diabetes mellitus.

Journal: Diabetic medicine : a journal of the British Diabetic Association

Published: April 27, 2018

Performance of claims-based algorithms for identifying incident thyroid cancer in commercial health plan enrollees receiving antidiabetic drug therapies.

Performance of claims-based algorithms for identifying incident thyroid cancer in commercial health plan enrollees receiving antidiabetic drug therapies.

Journal: BMC health services research

Published: November 16, 2016

Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes.

Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes.

Journal: Diabetes research and clinical practice

Published: September 09, 2016

Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden.

Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: March 08, 2016

Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study.

Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study.

Journal: Diabetes, obesity & metabolism

Published: December 01, 2015

Treatment beliefs, health behaviors and their association with treatment outcome in type 2 diabetes.

Treatment beliefs, health behaviors and their association with treatment outcome in type 2 diabetes.

Journal: BMJ open diabetes research & care

Published: October 24, 2015

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.

Journal: Diabetes, obesity & metabolism

Published: July 24, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026